Invizius Ltd

Based in Scotland, Invizius Ltd develops innovative complement therapeutics, focusing on treatments for autoimmune and inflammatory disorders. The company aims to address critical healthcare needs with its proprietary technology and therapeutic products. Invizius Ltd, founded in 2017 in Motherwell, UK, specializes in developing second-generation complement therapeutics. The company has received a total of 6 funding rounds, with the most recent deal occurring on June 18, 2024, in which it raised GBP 960,000 led by Mercia Asset Management along with participation from other investors.

The company is led by CEO Richard Boyd, while Andy Herbert is the founder. Invizius specializes in the development of second-generation complement therapeutics specifically designed to address autoimmune and inflammatory disorders. The company's lead product, H-Guard, is currently in clinical development and aims to meet significant unmet medical needs for patients undergoing dialysis and other extracorporeal circuit therapies. This proprietary technology enhances natural complement regulators, thereby maximizing patient safety and clinical efficacy.

Invizius primarily targets the healthcare sector, serving hospitals and medical facilities where patients require advanced treatment for inflammatory and fibrotic conditions. Although the company is based in the UK, its products have the potential to reach markets across North America, Europe, and Asia, depending on regulatory approvals and clinical trial outcomes. Invizius's revenue model is expected to revolve around partnerships with healthcare providers and procurement through hospital systems, focusing on direct-to-consumer sales within regulated environments. The company engages in B2B transactions, collaborating with healthcare institutions to integrate their products into treatment protocols.

H-Guard, as a flagship product, is positioned for distribution through specialized medical supply channels, where providers may procure the therapy for their patients. Revenue generation will primarily depend on the successful completion of clinical trials and securing necessary regulatory approvals, which are critical to determining the terms of sales agreements with healthcare organizations. Specific pricing plans for H-Guard and other products are established through negotiations with healthcare partners and are tailored to the market dynamics of the regions served. In June 2024, Invizius Ltd raised GBP 960,000 in venture funding to advance its Series B investment round scheduled for early next year and to prepare for the next round of clinical studies for its H-Guard product.

The company aims to expand its market presence, targeting North America, Europe, and Asia as potential regions for growth based on regulatory approval timelines and the outcomes of clinical trials.